U.S. Home Infusion Therapy Devices Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Home Infusion Therapy Devices
- ✓Market Size 2024: USD 1.9 billion
- ✓Market Size 2032: USD 3.3 billion
- ✓CAGR: 7.2%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Pursue Payer Contracts Early: Device makers should secure dispensing agreements with the top three commercial payers and Medicare Advantage plans in Texas and Florida before the 2026 plan year. Each contract locks pump standardization for three years and ties device adoption to reimbursement.
Home Infusion Devices in the United States: Market Overview
The United States accounts for the largest share of global home infusion activity, supported by a commercial payer base and a Medicare Part B benefit that pays for home-based intravenous care. Device demand here is concentrated in ambulatory electronic pumps, elastomeric pumps, and syringe drivers used by licensed home infusion pharmacies. Unlike markets where hospitals dispense most IV therapy, the U.S. model routes patients out of acute settings through specialty pharmacies, which reshapes device purchasing toward pharmacy fleets rather than hospital capital budgets.
Market value for devices reached roughly USD 1.9 billion in 2024, a segment that sits inside a broader home infusion services market several times larger. Growth is steady rather than explosive, with the device category expanding at about 7.2 percent annually as pharmacy operators replace aging fleets and add antibiotic and immunoglobulin programmes. The structure is fragmented at the pharmacy level, with national operators such as Option Care Health competing against thousands of regional providers, which keeps device purchasing price-sensitive and favours vendors with bundled service support.
Growth Drivers in U.S. Home Infusion Devices
Adults aged 65 and older number roughly 61 million, and Medicare beneficiaries drive most home infusion referrals for chronic conditions such as heart failure and primary immunodeficiency. The Consolidated Appropriations Act of 2021 created the Medicare Part B home infusion therapy benefit, effective January 2021, which compensates qualified providers for professional services delivered in the home. Pump demand follows this reimbursement pathway because external infusion pumps are covered under Medicare's durable medical equipment rules through LCD L33794.
Biologic and immunoglobulin therapy is the second driver. Hospitals and specialty pharmacies are moving IVIG for immunodeficiency and infliximab biosimilars into home settings, which requires ambulatory pumps with dose-accuracy alarms. Third, outpatient parenteral antibiotic therapy grows as hospitals discharge patients earlier under Medicare's diagnosis-related group payment model, shifting volumes toward elastomeric pumps that cost less than electronic units.
Market Restraints and Entry Barriers
Entry requires a state board of pharmacy license in every state of operation, plus accreditation from The Joint Commission or ACHC, a process that typically takes six to twelve months. USP General Chapter 797 governs sterile compounding and applies to any pharmacy preparing infusate, raising facility capital costs for operators. Device vendors also face downstream traceability obligations under the Drug Supply Chain Security Act, which adds data-handling costs for pharmacies that buy and dispense sterile products.
Incumbent pump platforms, notably BD Alaris and Baxter's Sigma Spectrum, hold installed bases across pharmacies and hospitals, and interoperability with pharmacy management software is the main switching barrier. Medicare pays pump rental under fixed durable medical equipment fee schedules, which compresses device margins for new entrants. Commercial payers frequently require pharmacies to use preferred vendors, so a new pump company must win a payer contract before any pharmacy will evaluate its hardware.
Market Opportunities in the United States
The nearest opportunity lies in connected pump platforms. Pharmacies want devices that log dose data directly to electronic health records and pharmacy management systems, and vendors offering standards-based interfaces gain preferred status with payers. Analyst estimates place annual pump replacement demand at roughly USD 420 million, with connectivity upgrades accounting for a growing share of that spend.
Sun Belt states, particularly Florida and Texas, combine fast-growing senior populations with thin pharmacy coverage, creating under-served catchment areas for new pharmacy fleets. A second opportunity sits in low-cost elastomeric pumps for outpatient antibiotic programmes, where a disposable device priced below USD 150 per unit fits bundled reimbursement economics. Vendors that pair these pumps with nursing-visit software can capture both device and service revenue.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.9 billion |
| Market Size 2032 | USD 3.3 billion |
| Growth Rate (CAGR) | 7.2% |
| Most Critical Decision Factor | Payer contract access and pump interoperability with pharmacy systems |
| Largest Region | South (Texas, Florida, and Southeast states) |
| Competitive Structure | Concentrated device suppliers with fragmented pharmacy operators |
Leading Market Participants
- Becton, Dickinson and Company
- Baxter International
- ICU Medical
- B. Braun Medical
- Fresenius Kabi
- InfuSystem Holdings
- Option Care Health
- KORU Medical Systems
- Hospira (Pfizer)
- Medline Industries
Regulatory and Policy Environment
The FDA regulates ambulatory infusion pumps as Class II devices under 21 CFR 880.5725 and requires 510(k) clearance before commercial sale. Section 524B of the Federal Food, Drug, and Cosmetic Act, added by the Consolidated Appropriations Act of 2023, requires cybersecurity documentation in premarket submissions for connected devices. Pharmacy-side compliance falls to state boards of pharmacy and USP Chapter 797, whose revised standards took effect in December 2023.
CMS sets Medicare home infusion therapy payments under the Part B benefit, with per-visit rates for professional services updated annually through the Physician Fee Schedule. Pump rental is paid under durable medical equipment rules, and CMS has proposed reinstating DMEPOS competitive bidding, with the next round expected to begin contracts in the late 2020s. Vendors should map their pump portfolios against these timelines to avoid pricing exposure during bid cycles.
Long-Term Outlook for U.S. Home Infusion Devices
By 2032 the device market is projected to reach USD 3.3 billion, with electronic pumps retaining majority share as connected platforms become the procurement standard. Consolidation among pharmacy operators will concentrate purchasing decisions in fewer national accounts, favouring suppliers with multi-state service contracts and nationwide technical support. Growth will track the senior population and the expansion of biologic IV therapies into home settings.
Competitive dynamics will shift as ICU Medical integrates the infusion portfolio acquired from Smiths Medical and as Baxter and BD defend installed bases through software upgrades. Subcutaneous alternatives will limit growth in certain therapy areas, but intravenous immunoglobulin and biosimilar infusions keep pump demand positive. Entrants that secure payer access before 2028 will hold durable positions in the market.
Frequently Asked Questions
Market Segmentation
- Ambulatory Electronic Infusion Pumps
- Elastomeric Infusion Pumps
- Syringe Drivers
- Infusion Sets and Accessories
- Home Infusion Pharmacies
- Hospice Agencies
- Skilled Nursing Facilities
- Self-Administering Patients
- Anti-infectives and OPAT
- Immunoglobulins
- Biologics
- Parenteral Nutrition
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.